1-9 of 9
David J. Kwiatkowski
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations

Elio Adib, Katarzyna Klonowska, Krinio Giannikou, Khanh T. Do, Solida Pruitt-Thompson, Ketki Bhushan, Matthew I. Milstein, Jennifer Hedglin, Katherine E. Kargus, Lynette M. Sholl, Junko Tsuji, David M. Hyman, Anne Sisk, Geoffrey I. Shapiro, Hebert A. Vargas, James J. Harding, Martin H. Voss, Gopa Iyer, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 3845–3853.
https://doi.org/10.1158/1078-0432.CCR-20-4548
Published: 15 July 2021
View article titled, Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations
Open the PDF for Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations in another window
Includes: Supplementary data
Journal Articles

CDKN2A Alterations and Response to Immunotherapy in Solid Tumors

Elio Adib, Amin H. Nassar, Elie W. Akl, Sarah Abou Alaiwi, Pier Vitale Nuzzo, Tarek H. Mouhieddine, Guru Sonpavde, Robert I. Haddad, Kent W. Mouw, Marios Giannakis, F. Stephen Hodi, Sachet A. Shukla, Alexander Gusev, David A. Braun, Toni K. Choueiri, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (14): 4025–4035.
https://doi.org/10.1158/1078-0432.CCR-21-0575
Published: 15 July 2021
View article titled, <em>CDKN2A</em> Alterations and Response to Immunotherapy in Solid Tumors
Open the PDF for <em>CDKN2A</em> Alterations and Response to Immunotherapy in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites

Amin H. Nassar, Renato Umeton, Jaegil Kim, Kevin Lundgren, Lauren Harshman, Eliezer M. Van Allen, Mark Preston, Fei Dong, Joaquim Bellmunt, Kent W. Mouw, Toni K. Choueiri, Guru Sonpavde, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (8): 2458–2470.
https://doi.org/10.1158/1078-0432.CCR-18-3147
Published: 15 April 2019
View article titled, Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites
Open the PDF for Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites in another window
Includes: Supplementary data
Journal Articles

Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases

Fengju Chen, Yiqun Zhang, Don L. Gibbons, Benjamin Deneen, David J. Kwiatkowski, Michael Ittmann, Chad J. Creighton
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (9): 2182–2193.
https://doi.org/10.1158/1078-0432.CCR-17-3378
Published: 30 April 2018
View article titled, Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Open the PDF for Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases in another window
Includes: Supplementary data
Journal Articles

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Michael R. Rossi, Heidi Chen, Junya Fujimoto, Andre L. Moreira, Suresh S. Ramalingam, Liza C. Villaruz, Gregory A. Otterson, Eric Haura, Katerina Politi, Bonnie Glisson, Jeremy Cetnar, Edward B. Garon, Joan Schiller, Saiama N. Waqar, Lecia V. Sequist, Julie Brahmer, Yu Shyr, Kelly Kugler, Ignacio I. Wistuba, Bruce E. Johnson, John D. Minna, Mark G. Kris, Paul A. Bunn, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (5): 1038–1047.
https://doi.org/10.1158/1078-0432.CCR-17-2289
Published: 28 February 2018
View article titled, The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
Open the PDF for The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) in another window
Includes: Supplementary data
Journal Articles

Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

David J. Kwiatkowski, Toni K. Choueiri, André P. Fay, Brian I. Rini, Aaron R. Thorner, Guillermo de Velasco, Magdalena E. Tyburczy, Lana Hamieh, Laurence Albiges, Neeraj Agarwal, Thai H. Ho, Jiaxi Song, Jean-Christophe Pignon, Pablo M. Barrios, M. Dror Michaelson, Eliezer M. Van Allen, Katherine M. Krajewski, Camillo Porta, Sumanta Kumar Pal, Joaquim Bellmunt, David F. McDermott, Daniel Y.C. Heng, Kathryn P. Gray, Sabina Signoretti
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (10): 2445–2452.
https://doi.org/10.1158/1078-0432.CCR-15-2631
Published: 12 May 2016
View article titled, Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma
Open the PDF for Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise

Jaegil Kim, Rehan Akbani, Chad J. Creighton, Seth P. Lerner, John N. Weinstein, Gad Getz, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (20): 4514–4524.
https://doi.org/10.1158/1078-0432.CCR-14-1215
Published: 14 October 2015
View article titled, Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise
Open the PDF for Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise in another window
Journal Articles

Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma

Markus Riester, Lillian Werner, Joaquim Bellmunt, Shamini Selvarajah, Elizabeth A. Guancial, Barbara A. Weir, Edward C. Stack, Rachel S. Park, Robert O'Brien, Fabio A.B. Schutz, Toni K. Choueiri, Sabina Signoretti, Josep Lloreta, Luigi Marchionni, Enrique Gallardo, Federico Rojo, Denise I. Garcia, Yvonne Chekaluk, David J. Kwiatkowski, Bernard H. Bochner, William C. Hahn, Azra H. Ligon, Justine A. Barletta, Massimo Loda, David M. Berman, Philip W. Kantoff, Franziska Michor, Jonathan E. Rosenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (7): 1873–1883.
https://doi.org/10.1158/1078-0432.CCR-13-0759
Published: 31 March 2014
View article titled, Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Open the PDF for Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma in another window
Includes: Supplementary data
Journal Articles

Gelsolin as a Negative Prognostic Factor and Effector of Motility in erbB-2-positive Epidermal Growth Factor Receptor-positive Breast Cancers

Ann D. Thor, Susan M. Edgerton, Shuqing Liu, Dan H. Moore, II, David J. Kwiatkowski
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2415–2424.
Published: 01 August 2001
View article titled, Gelsolin as a Negative Prognostic Factor and Effector of Motility in erbB-2-positive Epidermal Growth Factor Receptor-positive Breast Cancers
Open the PDF for Gelsolin as a Negative Prognostic Factor and Effector of Motility in erbB-2-positive Epidermal Growth Factor Receptor-positive Breast Cancers in another window